No internet connection — showing the saved version of the page.

Sanofi ADR

USUSD
← to the screener

Sanofi ADR (PA:SAN) — Biotechnology: Pharmaceutical Preparations. Number of exchanges where the company shares trade: 6. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
sanofi.com
Sector
Health Care · Biotechnology: Pharmaceutical Preparations
Headquarters
PARIS, France
CEO
Paul Hudson
Employees
106 566
Founded
2004
Listed since
03.01.2000 (PA:SAN)
Shares outstanding
1.22 B as of 2025-12-31
Free float
2.16 B
Market cap
98.67 B USD
Insiders
0%
Institutions
8.02%
Industry (SIC)
Pharmaceutical Preparations
Legal form
QVPB
ISIN
FR0000120578
LEI
549300E9PC51EN656011
P/E
22.2
Payout ratio
≈64.0%
FCF
10.8 B EUR
Payout / FCF
47%
Debt
18.7 B EUR
1.0 y of FCF
Dividend streak
23 y
Earnings, FCF and dividends paid — for the 12 months to 31.12.2025 (the company's latest report).
NAV
58.53 EUR · P/NAV 1.23
Balance sheet date31.12.2025
Assets127 B EUR
− Liabilities55.1 B EUR
= Total equity71.7 B EUR
− Non-controlling interests334 M EUR
= NAV (equity of the company's shareholders)71.4 B EUR
− Goodwill41.3 B EUR
− Intangible assets26.3 B EUR
= Tangible NAV3.82 B EUR
Shares1 219 427 096
NAV per share58.53 EUR
Tangible NAV per share3.13 EUR
Share price (SAN)72.1600 EUR
P/NAV1.23
NAV history
Balance sheet dateNAVNAV per share
31.12.202571.4 B EUR58.53 EUR
31.12.202477.5 B EUR61.36 EUR
31.12.202374.0 B EUR58.54 EUR
31.12.202274.8 B EUR59.31 EUR
31.12.202168.7 B EUR54.36 EUR
31.12.202063.1 B EUR50.46 EUR
31.12.201959.1 B EUR47.10 EUR
31.12.201858.9 B EUR47.27 EUR
Description

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
US USA StocksSNYNF OTCUSD78.17 +1.84%common stock
LSE London Stock Exchange0O59 IOBEUR71.63 +0.72%common stock
MI Borsa Italiana (Milan)1SAN secondaryEUR72.38 +1.26%common stock
PA Euronext ParisSAN primaryEUR72.16 +0.47%common stock
VI Vienna Stock ExchangeSANO secondaryEUR71.3 +1.03%common stock
XETRA XetraSNW secondaryEUR71.78 -1.21%common stock

Price for 3 months

up day down day dividend ex-date payment dateHover / tap a day — open, close, high and low prices

Dividends

Per year, PA:SAN: 4.12 EUR (1 paym.)

Sanofi ADR (SAN) pays dividends once a year. Per year (12 months up to and including the latest announced payment): 4.12 EUR per share (payments: 1). That is about 5.71% of the current share price. Based on payment history, the next ex-dividend date is expected around 04.05.2027. Uninterrupted dividend history: 23 years.

Ex-datePaymentAmount%TypeTicker
2026-05-052026-05-074.1200 EUR5.3/5.3 %annualPA:SAN
2025-05-122025-05-143.9200 EUR4.2/4.2 %annualPA:SAN
2024-05-132024-05-153.7600 EUR4.0/7.8 %annualPA:SAN
2023-05-30—3.5600 EUR3.6/3.6 %annualPA:SAN
2022-05-06—3.3300 EUR3.3/3.3 %annualPA:SAN

Top holders

HolderStakeSharesReport date
Dodge & Cox Inc.10.54%28.09 M2026-06-30
Dodge & Cox Funds-Dodge…7.84%20.9 M2026-06-30
Morgan Stanley4.02%10.7 M2026-06-30
Fisher Asset Management,…3.99%10.63 M2026-06-30
Bank of America Corporat…3%8.01 M2026-06-30
Invesco Ltd.2.55%6.8 M2026-06-30
JPMORGAN CHASE & CO2.47%6.57 M2026-06-30
Mondrian Investment Part…2.07%5.52 M2026-06-30
Brandes Investment Partn…1.55%4.14 M2026-06-30
AIM Sector Funds (Invesc…1.51%4.03 M2026-04-30
Federated Hermes, Inc.1.44%3.85 M2026-06-30
Boston Partners1.44%3.84 M2026-06-30
VANGUARD STAR FUNDS-Vang…1.31%15.85 M2026-07-31
Putnam ETF Trust-Putnam…1.26%3.36 M2026-05-31
VANGUARD TAX-MANAGED FUN…0.87%10.53 M2026-06-30
iShares Trust-iShares Co…0.67%8.11 M2026-08-31
Dodge & Cox Funds-Dodge…0.63%1.67 M2026-06-30
AMERICAN MUTUAL FUND0.59%1.58 M2026-06-30
American Century Capital…0.37%976 5612026-06-30
Bridge Builder Trust-Bri…0.36%967 1002026-06-30
Fidelity Concord Street…0.35%4.24 M2026-07-31
VanEck ETF Trust-VanEck…0.35%938 5612026-08-31
Dodge & Cox Funds-Dodge…0.33%4.04 M2026-06-30
iShares Trust-iShares MS…0.32%3.89 M2026-08-31
Capital World Growth & I…0.3%3.67 M2026-06-30
-Victory Pioneer Core Eq…0.3%799 4872026-06-30
Fidelity Covington Trust…0.3%797 1842026-08-31
NEW PERSPECTIVE FUND0.29%3.56 M2026-06-30
Federated Hermes Eqy. Fd…0.29%3.48 M2026-07-31
Bridge Builder Trust-Bri…0.29%3.44 M2026-06-30
Pacer Advisors, Inc.0.1%1.16 M2026-06-30
Generali Investments Cee…0%29 3392026-06-30
Paradigm Asset Managemen…0%19 2002026-06-30
Gamma Investing LLC0%582026-06-30
L'Oréal———